Orphi Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Orphi Therapeutics General Information

Description

Developer of a biotech therapy designed to develop pharmacological chaperones (PCs) for the treatment of monogenic diseases. The company's therapy is insisted with MC4R-linked monogenic obesity and Sandhoff/Tay Sachs disease, enabling patients to treat blood disorders, cerebral amyloid angiopathy or "CAA," which can cause strokes with medical therapy.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Therapeutic Devices
Primary Office
  • 7276 Golfcrest Drive
  • San Diego, CA 92119
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orphi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 23-Aug-2021 00000 Completed Out of Business
4. Grant 01-Jan-2017 00.000 00000 Completed Product Development
3. Grant 17-Sep-2015 0000 00000 Completed Product Development
2. Early Stage VC 18-May-2015 $650K $650K Completed Product Development
1. Grant 01-Jan-2015 $375K Completed Product Development
To view Orphi Therapeutics’s complete valuation and funding history, request access »